Patient Requests are a Key Driver Behind Switching Brands in Rheumatoid Arthritis, according to a Recently Released Study by Spherix Global Insights Download Report Overview EXTON, Pa., Oct. 16, 2017 /PRNewswire/ — Spherix Global Insights announces the release of the…
While Copaxone brand loyalists and therapeutic equivalence concerns remain, the preference for three-times-weekly dosing will diminish reluctance to initiate generics, according to the most recent quarterly update by Spherix Global Insights Download Report Overview EXTON, Pa., Oct. 4, 2017 /PRNewswire/…
According to Spherix Global Insights, the analysis indicates an increase in biologic switching rates compared to the prior year with a growing movement away from TNF cycling, opening doors for earlier use of alternative mechanism agents Download Report Overview EXTON,…
As previously predicted, Ocrevus trial and share has increased significantly, positioning the new market entrant as second only to Biogen’s Tysabri in the mAb DMT class, according to the most recent quarterly update by Spherix Global Insights Download Report Overview…
According to Spherix Global Insight’s latest quarterly release of RealTime Dynamix™: Psoriasis, dermatologists are feeling increasingly overwhelmed with the sheer number of new biologic entrants recently approved in the US. Download Report Overview EXTON, Pa., Sept. 14, 2017 /PRNewswire/ —…
Despite Remicade’s status as the go-to agent in ulcerative colitis (UC), the introduction and adoption of the biosimilar Inflectra appears to be having an impact on the brand, with share for Janssen’s branded infliximab significantly down compared to the same…